PL3697818T3 - Leczenie CD20-dodatniego chłoniaka z limfocytów B obinutuzumabem - Google Patents

Leczenie CD20-dodatniego chłoniaka z limfocytów B obinutuzumabem

Info

Publication number
PL3697818T3
PL3697818T3 PL18804720.3T PL18804720T PL3697818T3 PL 3697818 T3 PL3697818 T3 PL 3697818T3 PL 18804720 T PL18804720 T PL 18804720T PL 3697818 T3 PL3697818 T3 PL 3697818T3
Authority
PL
Poland
Prior art keywords
obinutuzumab
positive
treatment
cell lymphoma
lymphoma
Prior art date
Application number
PL18804720.3T
Other languages
English (en)
Polish (pl)
Inventor
Michael Wenger
Mehrdad Mobasher
Chin-Yu Lin
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64362606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3697818(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL3697818T3 publication Critical patent/PL3697818T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
PL18804720.3T 2017-10-19 2018-10-19 Leczenie CD20-dodatniego chłoniaka z limfocytów B obinutuzumabem PL3697818T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762574297P 2017-10-19 2017-10-19
PCT/JP2018/038924 WO2019017499A2 (en) 2017-10-19 2018-10-19 PHARMACEUTICAL COMPOSITION

Publications (1)

Publication Number Publication Date
PL3697818T3 true PL3697818T3 (pl) 2025-03-24

Family

ID=64362606

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18804720.3T PL3697818T3 (pl) 2017-10-19 2018-10-19 Leczenie CD20-dodatniego chłoniaka z limfocytów B obinutuzumabem

Country Status (14)

Country Link
US (2) US12129304B2 (cg-RX-API-DMAC7.html)
EP (2) EP3697818B1 (cg-RX-API-DMAC7.html)
JP (2) JP6860652B2 (cg-RX-API-DMAC7.html)
KR (1) KR102766089B1 (cg-RX-API-DMAC7.html)
CN (2) CN111212854A (cg-RX-API-DMAC7.html)
AU (2) AU2018303836B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020007731A2 (cg-RX-API-DMAC7.html)
CA (1) CA3079374A1 (cg-RX-API-DMAC7.html)
ES (1) ES3005784T3 (cg-RX-API-DMAC7.html)
IL (2) IL321935A (cg-RX-API-DMAC7.html)
MX (2) MX419643B (cg-RX-API-DMAC7.html)
PL (1) PL3697818T3 (cg-RX-API-DMAC7.html)
TW (2) TWI805630B (cg-RX-API-DMAC7.html)
WO (1) WO2019017499A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI805630B (zh) * 2017-10-19 2023-06-21 瑞士商赫孚孟拉羅股份公司 醫藥組合物
AU2020356896A1 (en) * 2019-10-04 2022-05-19 Chugai Seiyaku Kabushiki Kaisha Inhibitor of cell proliferation in obinutuzumab resistant CD20-positive cancer, and medicinal composition, medicine, production, method for inhibiting cell proliferation, therapeutic method, type II anti-CD20 antibody, compounds, combination of same, enhancer and inducer, each relating thereto
CN117941219A (zh) 2021-09-17 2024-04-26 佳能株式会社 送电设备和受电设备

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55723B1 (sr) 2003-11-05 2017-07-31 Roche Glycart Ag Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
ES2511844T3 (es) 2007-12-21 2014-10-23 F. Hoffmann-La Roche Ag Formulación de anticuerpo
HRP20220738T1 (hr) 2014-08-11 2022-08-19 Acerta Pharma B.V. Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1
US11149091B2 (en) * 2015-12-09 2021-10-19 Cedars-Sinai Medical Center Methods for treating nephrotic syndrome
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
EP3656814B1 (en) 2017-07-21 2025-12-24 The Yokohama Rubber Co., Ltd. Pneumatic tire
TWI805630B (zh) * 2017-10-19 2023-06-21 瑞士商赫孚孟拉羅股份公司 醫藥組合物

Also Published As

Publication number Publication date
IL273909A (en) 2020-05-31
JP6860652B2 (ja) 2021-04-21
BR112020007731A2 (pt) 2020-10-20
IL273909B1 (en) 2025-08-01
AU2018303836A1 (en) 2020-05-14
KR20200067196A (ko) 2020-06-11
MX419643B (es) 2025-01-14
CA3079374A1 (en) 2019-01-24
MX2020003418A (es) 2020-07-20
ES3005784T3 (en) 2025-03-17
JP2019528282A (ja) 2019-10-10
TWI805630B (zh) 2023-06-21
JP2021152002A (ja) 2021-09-30
TWI828593B (zh) 2024-01-01
AU2018303836B2 (en) 2025-04-17
KR102766089B1 (ko) 2025-02-13
EP3697818B1 (en) 2024-11-27
US20200299398A1 (en) 2020-09-24
IL273909B2 (en) 2025-12-01
US20250026847A1 (en) 2025-01-23
AU2025205481A1 (en) 2025-08-07
KR20240157135A (ko) 2024-10-31
TW202342099A (zh) 2023-11-01
EP4520347A3 (en) 2025-06-04
IL321935A (en) 2025-09-01
TW201922284A (zh) 2019-06-16
EP4520347A2 (en) 2025-03-12
WO2019017499A3 (en) 2019-02-21
JP7370357B2 (ja) 2023-10-27
CN111212854A (zh) 2020-05-29
US12129304B2 (en) 2024-10-29
MX2024009217A (es) 2024-11-08
EP3697818A2 (en) 2020-08-26
CN120983618A (zh) 2025-11-21
WO2019017499A2 (en) 2019-01-24

Similar Documents

Publication Publication Date Title
EP3615040C0 (en) HAIR TREATMENT COMPOSITIONS
LT3661514T (lt) Mavakamtenas, skirtas naudoti gydant hipertrofinę kardiomiopatiją
IL285771A (en) Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
PL3317284T3 (pl) Związki oksazolidynonu benzoksazepiny i sposoby stosowania
EP3757187A4 (en) SURFACE TREATMENT AGENT
PT3182996T (pt) Métodos de tratamento de mieloma múltiplo com compostos imunomoduladores em combinação com anticorpos
DK3897672T3 (da) Hbv kombinationsbehandling
EP3741810A4 (en) SILICONE COMPOSITION
EP3626119A4 (en) APPLICATOR
EP3512553A4 (en) KLRG1 EXHAUST THERAPY
DK3530786T3 (da) Blød tvindings-frotté-artikel
HUE063528T2 (hu) Anti-CD40 antitestek alkalmazása lupus nephritis kezelésére
TWI800561B (zh) 毛髮處理方法
DE112019002443A5 (de) Applikator
EP3627536A4 (en) SUSCEPTOR
EP3999100C0 (en) ENHANCED TREATMENT WITH EYP001
EP3604708A4 (en) BELT HOLDER
EP3906000A4 (en) RESEALABLE WOUND DRESSING
EP3881899A4 (en) Cosmetic
PL3697818T3 (pl) Leczenie CD20-dodatniego chłoniaka z limfocytów B obinutuzumabem
IL281839A (en) Treatment methods
IL281792A (en) Treatment methods
IL280968A (en) Combination therapy
EP3578162A4 (en) HAIR TREATMENT METHOD
EP3773448C0 (en) HAIR TREATMENT PROCESS